ClinicalTrials.gg
RecruitingNCT07247058Updated Oct 23, 2026

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

A Phase 4 interventional study of Osilodrostat (Isturisa) in Mild Autonomous Cortisol Secretion (MACS), sponsored by Johns Hopkins University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Johns Hopkins University · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 23, 2026Eligibility revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · United States.

Planned enrollment
27th of 38
10 · median 22
Started
2026
with 4 others
Phase 4
Only one
of the 50
Primary completion
2028-12
later than 7 of 12 live
Registered
48th of 50
by date

Among the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, this one is the 27th largest by planned enrollment of the 38 interventional ones that give a count, is one of 5 that started in 2026, is the only one in phase 4, reaches primary completion later than 7 of the 12 other live ones, and was the 48th registered.

Adrenal Hyperplasia, Congenital

102 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 29 are open to participants now.

Browse Adrenal Hyperplasia, Congenital studies →

Open to participants now

10 of the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, or all of them as a file.
02

Study summary

To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.

Read the detailed description

Mild autonomous cortisol secretion (MACS) is diagnosed in up to 48% of patients with incidentally discovered adrenal tumors or hyperplasia. Based on the finding of adrenal masses in 5% of adults undergoing cross-sectional imaging, the overall prevalence of MACS is about 1-2%. MACS is characterized by autonomous cortisol secretion without the overt symptoms of Cushing syndrome. It is usually associated with low ACTH and DHEAS levels as an indicator of autonomous cortisol secretion. The European Society of Endocrinology-European Network for the Study of Adrenal Tumors (ESE-ENSAT) and the American Association of Clinical Endocrinology (AACE) recommend a cortisol >1.8 μg/dL after 1 mg-DST to define MACS. Several metabolic abnormalities are associated with MACS, including increased cardiovascular disease, mood alteration, hypertension, osteoporosis, hyperglycemia, obesity, weight gain, and lipid abnormalities. Additionally, increased mortality has been reported in MACS patients. Given these complications and increased mortality, there is a need for effective management and treatment options for MACS.

This research aims to evaluate the efficacy and safety of Isturisa in patients with MACS to address the current gap in treatment strategies. By assessing how effectively Isturisa improves cardiometabolic disorders and monitoring its safety profile, the research will seek to provide a clearer understanding of its role as a treatment option in MACS patients who are not a surgical candidate or do not want to pursue surgery. This evaluation is crucial for developing more effective treatment options and improving management strategies for MACS, ultimately contributing to better patient management.

03

Conditions studied

  • Mild Autonomous Cortisol Secretion (MACS)

Keywords

  • MACS
  • Mild Autonomous Cortisol Secretion
  • Adrenal Adenoma
  • Osilodrostat
  • Isturisa
  • Body Composition
  • Metabolic Outcomes
  • Subclinical Cushing Syndrome
  • Adrenal hyperplasia
  • Carotid intima thickness
  • Bone mineral density
  • Hypertension
  • Glycemic control
04

Who can participate

The criteria were revised on the registry on Oct 23, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Age >18 years old with confirmed mild autonomous cortisol secretion (MACS) Cushing's syndrome, defined by:

    • At least two abnormal 1 mg Dexamethasone suppression tests (Cortisol > 1.8 ug/dL at 8-9 am after taking 1 mg dexamethasone at 11 pm) with appropriate dexamethasone level for the assay (last level within 3 months before enrollment).
    • Having at least two early morning fasting ACTH \<15 pg/mL (last level within 3 months before enrollment)
  • Presence of at least one of the following comorbidities:

    • The presence of prediabetes or Type 2 diabetes mellitus (T2DM): fasting plasma glucose ≥100 mg/dL and/or 2-hour Oral Glucose Tolerance Test (OGTT) glucose ≥140 mg/dL, or ≥5.7%
    • Systolic hypertension is defined as a mean Systolic Blood Pressure (SBP) ≥130 mmHg after 5 min rest in a seated position (mean of 3 blood pressure measurements 5 minutes apart) irrespective of the number of anti-hypertensive medications.
    • >30 kg/m2
  • The presence of an adrenal adenoma or hyperplasia, as determined by CT or MRI studies
  • Negative urine pregnancy test at Baseline (urine) for women of

Exclusion criteria:

  • Has severe, uncontrolled hypertension (mean SBP >170 mm Hg or mean Diastolic Blood Pressure (DBP) >110 mm Hg at Screening)
  • Has poorly controlled DM (HbA1c >11% at Screening).
  • Has abnormal liver test results (total >1.5× or elevated or aspartate aminotransferase >3×ULN at Baseline).
  • Has severe renal insufficiency ( ≤29 mL/min at Baseline).
  • Has uncontrolled, hypothyroidism or hyperthyroidism.
  • Has prolonged corrected for heart rate using Fridericia's equation (QTcF) (>450 ms for men and >470 ms for women) with a normal QRS interval (\<120 ms) or QTcF interval >500 ms with wide QRS interval (≥120 ms).
  • Has persistent atrial fibrillation.
  • Has uncorrected hypokalemia.
  • Has used or plans to use any treatments for MACS within 12 weeks before Screening and throughout the study, including metyrapone, mifepristone, ketoconazole, fluconazole, or any drug for the treatment of hypercortisolism.
  • Has adrenocortical carcinoma, or the adrenal images are suspicious for an underlying .
  • Has autonomous co-secretion of aldosterone.
  • Has plans for adrenalectomy or nodulectomy during the study.
  • Pregnancy, lactating, or intends to become pregnant in the next 2 years.
  • Female patients of childbearing potential who cannot use a highly effective method of , including all women \<50 years old, women whose surgical sterilization was performed \<6 months ago.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Isturisa Treatment Arm

    Participants diagnosed with Mild Autonomous Cortisol Secretion (MACS) will receive Osilodrostat (Isturisa) as an investigational treatment. The intervention aims to evaluate comorbidities associated with MACS after the initiation of osilodrostat(Isturisa).

    Drug: Osilodrostat (Isturisa)

Interventions

  • DrugOsilodrostatStudies of OsilodrostatOsilodrostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The intervention aims to evaluate the impact of osilodrostat on cardiometabolic outcomes, bone mineral density, body composition, adrenal tumor size or hyperplasia, and biochemical markers of cortisol excess.

    Also known as: Osilodrostat, Isturisa, LCI699

06

What researchers measure

Primary outcomes

  1. Change in fasting glucose, HbA1c

    glycemic control: fasting glucose, HbA1c

    Time frame: Baseline, and then every 3 months up to 2 years

  2. Change in bone mineral density (g/cm²)

    Bone mineral density (g/cm²) measured by DEXA scan.

    Time frame: Baseline, 1 year, and 2 years

  3. Change in body weight (kg) from baseline during Isturisa treatment

    Change in body weight will be measured at baseline and every follow-up visit (approximately every 3 months) throughout the 2-year treatment period with Isturisa.

    Time frame: Baseline and every 3 months up to 2 years

  4. Change in lipid profile from baseline during Isturisa treatment

    Serum lipid profile (LDL-C, HDL-C, total cholesterol, triglycerides) will be assessed at baseline and every follow-up visit (approximately every 3 months) during the 2-year treatment period.

    Time frame: Baseline and every 3 months up to 2 years

  5. Change in body composition (kg)

    Body composition including lean mass and fat mass (kg) measured by DEXA scan.

    Time frame: baseline, 1 year and 2 years

Secondary outcomes

  1. Change in Quality of Life as assessed by Short Form -36 (SF-36)

    Assessment of changes in quality of life using the SF-36 Health Survey. The SF-36 consists of 36 items measuring 8 health domains, with total scores ranging from 0 to 100, where higher scores indicate better quality of life.

    Time frame: Baseline and every 3 months up to 2 years

  2. Change in carotid intima-media thickness (CIMT)

    Carotid intima-media thickness (milimeters) will be measured using carotid ultrasound to evaluate vascular changes associated with mild autonomous cortisol secretion. CIMT will be assessed at baseline and at follow-up imaging performed approximately every 12 months during the 2-year treatment period.

    Time frame: Baseline, 1 year, and 2 years

  3. Change in adrenal adenoma/hyperplasia size (mm)

    Adenoma maximal diameter (mm) measured on non-contrast CT at each imaging time point.

    Time frame: Baseline, 1 year, and 2 years

  4. Change in Depression Scores as assessed by the Beck Depression Inventory-II

    Assessment of changes in depressive symptoms using the Beck Depression Inventory-II (BDI-II). The BDI-II is a 21-item validated questionnaire with total scores ranging from 0 to 63, where higher scores indicate more severe depressive symptoms.

    Time frame: Baseline and every 3 months up to 2 years

Other outcomes

  1. Change in Inflammatory Biomarkers

    Exploratory evaluation of changes in inflammatory biomarkers, specifically high-sensitivity C-reactive protein (hsCRP) and interleukin-6 (IL-6), during treatment with Isturisa in patients with mild autonomous cortisol secretion (MACS). These markers are included in the optional research-specific procedures to assess potential inflammatory or physiologic effects of Isturisa beyond cortisol regulation.

    Time frame: Baseline and every 3 months up to 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Feldman D. Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev. 1986 Nov;7(4):409-20. doi: 10.1210/edrv-7-4-409. No abstract available. PubMed 3536461 ↗
  • Martino M, Aboud N, Lucchetti B, Salvio G, Arnaldi G. Osilodrostat oral tablets for adults with Cushing's disease. Expert Rev Endocrinol Metab. 2022 Mar;17(2):99-109. doi: 10.1080/17446651.2022.2044789. Epub 2022 Feb 28. PubMed 35220871 ↗
  • Tibblin S, Dymling JF, Ingemansson S, Telenius-Berg M. Unilateral versus bilateral adrenalectomy in multiple endocrine neoplasia IIA. World J Surg. 1983 Mar;7(2):201-8. doi: 10.1007/BF01656143. No abstract available. PubMed 6135282 ↗
  • Ma L, Yin L, Hu Q. Therapeutic compounds for Cushing's syndrome: a patent review (2012-2016). Expert Opin Ther Pat. 2016 Nov;26(11):1307-1323. doi: 10.1080/13543776.2016.1217331. Epub 2016 Jul 30. PubMed 27454103 ↗
  • Ren X, Nan M, Zhang X. Evaluating the efficacy of surgical and conservative approaches in mild autonomous cortisol secretion: a meta-analysis. Front Endocrinol (Lausanne). 2024 Jul 17;15:1399311. doi: 10.3389/fendo.2024.1399311. eCollection 2024. PubMed 39086899 ↗
  • Sbardella E, Minnetti M, D'Aluisio D, Rizza L, Di Giorgio MR, Vinci F, Pofi R, Giannetta E, Venneri MA, Vestri A, Morelli S, Lenzi A, Isidori AM. Cardiovascular features of possible autonomous cortisol secretion in patients with adrenal incidentalomas. Eur J Endocrinol. 2018 May;178(5):501-511. doi: 10.1530/EJE-17-0986. Epub 2018 Mar 6. PubMed 29510982 ↗
  • Patrova J, Kjellman M, Wahrenberg H, Falhammar H. Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center. Endocrine. 2017 Nov;58(2):267-275. doi: 10.1007/s12020-017-1400-8. Epub 2017 Sep 8. PubMed 28887710 ↗
  • Pelsma ICM, Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis. Eur J Endocrinol. 2023 Oct 17;189(4):S88-S101. doi: 10.1093/ejendo/lvad134. PubMed 37801655 ↗
  • Czapla-Iskrzycka A, Swiatkowska-Stodulska R, Sworczak K. Comorbidities in Mild Autonomous Cortisol Secretion - A Clinical Review of Literature. Exp Clin Endocrinol Diabetes. 2022 Sep;130(9):567-576. doi: 10.1055/a-1827-4113. Epub 2022 Jul 11. PubMed 35817047 ↗
  • Vaidya A, Hamrahian A, Bancos I, Fleseriu M, Ghayee HK. THE EVALUATION OF INCIDENTALLY DISCOVERED ADRENAL MASSES. Endocr Pract. 2019 Feb;25(2):178-192. doi: 10.4158/DSCR-2018-0565. PubMed 30817193 ↗
  • Fassnacht M, Tsagarakis S, Terzolo M, Tabarin A, Sahdev A, Newell-Price J, Pelsma I, Marina L, Lorenz K, Bancos I, Arlt W, Dekkers OM. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2023 Jul 20;189(1):G1-G42. doi: 10.1093/ejendo/lvad066. PubMed 37318239 ↗
  • Trandafir AI, Ghemigian A, Ciobica ML, Nistor C, Gurzun MM, Nistor TVI, Petrova E, Carsote M. Diabetes Mellitus in Non-Functioning Adrenal Incidentalomas: Analysis of the Mild Autonomous Cortisol Secretion (MACS) Impact on Glucose Profile. Biomedicines. 2024 Jul 18;12(7):1606. doi: 10.3390/biomedicines12071606. PubMed 39062179 ↗
  • Zavatta G, Vicennati V, Altieri P, Tucci L, Colombin G, Coscia K, Mosconi C, Balacchi C, Fanelli F, Malagrino M, Magagnoli M, Golfieri R, Pagotto U, Di Dalmazi G. Mild autonomous cortisol secretion in adrenal incidentalomas and risk of fragility fractures: a large cross-sectional study. Eur J Endocrinol. 2023 Apr 4;188(4):343-352. doi: 10.1093/ejendo/lvad038. PubMed 36952249 ↗
  • Delivanis DA, Athimulam S, Bancos I. Modern Management of Mild Autonomous Cortisol Secretion. Clin Pharmacol Ther. 2019 Dec;106(6):1209-1221. doi: 10.1002/cpt.1551. Epub 2019 Aug 6. PubMed 31206616 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2026 (actual). Primary completion is estimated for Dec 2028, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2025
First posted
Nov 25, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Mar 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
Criteria largely rewritten (35 changes)
What changed in the criteria
  • EditedDiagnosis ofAge >18 years old with confirmed mild autonomous cortisol secretion (MACS) Cushing's syndrome, defined by:
  • AddedAt least two abnormal 1 mg Dexamethasone suppression tests (Cortisol > 1.8 ug/dL at 8-9 am after taking 1 mg dexamethasone at 11 pm) with appropriate dexamethasone level for the assay (last level within 3 months before enrollment).
  • AddedHaving at least two early morning fasting ACTH <15 pg/mL (last level within 3 months before enrollment)
  • AddedPresence of at least one of the following comorbidities:
  • AddedThe presence of prediabetes or Type 2 diabetes mellitus (T2DM): fasting plasma glucose ≥100 mg/dL and/or 2-hour Oral Glucose Tolerance Test (OGTT) glucose ≥140 mg/dL, or HbA1c ≥5.7%
  • AddedSystolic hypertension is defined as a mean Systolic Blood Pressure (SBP) ≥130 mmHg after 5 min rest in a seated position (mean of 3 blood pressure measurements 5 minutes apart) irrespective of the number of anti-hypertensive medications.
  • AddedBMI >30 kg/m2
  • EditedPresenceThe presence of an adrenal adenoma confirmedor hyperplasia, as determined by imaging (CT or MRI). studies
  • AddedNegative urine pregnancy test at Baseline (urine) for women of childbearing potential
  • AddedExclusion criteria:
  • AddedHas severe, uncontrolled hypertension (mean SBP >170 mm Hg or mean Diastolic Blood Pressure (DBP) >110 mm Hg at Screening)
  • AddedHas poorly controlled DM (HbA1c >11% at Screening).
  • AddedHas abnormal liver test results (total bilirubin >1.5×ULN or elevated alanine aminotransferase or aspartate aminotransferase >3×ULN at Baseline).
  • AddedHas severe renal insufficiency (glomerular filtration rate ≤29 mL/min at Baseline).
  • AddedHas uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
  • AddedHas prolonged QT interval corrected for heart rate using Fridericia's equation (QTcF) (>450 ms for men and >470 ms for women) with a normal QRS interval (<120 ms) or QTcF interval >500 ms with wide QRS interval (≥120 ms).
  • AddedHas persistent atrial fibrillation.
  • AddedHas uncorrected hypokalemia.
  • AddedHas used or plans to use any treatments for MACS within 12 weeks before Screening and throughout the study, including metyrapone, mifepristone, ketoconazole, fluconazole, or any investigational drug for the treatment of hypercortisolism.
  • AddedHas adrenocortical carcinoma, or the adrenal images are suspicious for an underlying malignancy.
  • AddedHas autonomous co-secretion of aldosterone.
  • AddedHas plans for adrenalectomy or nodulectomy during the study.
  • AddedPregnancy, lactating, or intends to become pregnant in the next 2 years.
  • AddedFemale patients of childbearing potential who cannot use a highly effective method of contraception, including all women <50 years old, women whose surgical sterilization was performed <6 months ago.
Inclusion criteria
  • RemovedAdults aged ≥18 years.
  • RemovedSerum cortisol >1.8 µg/dL after 1 mg overnight dexamethasone suppression test (DST).
  • RemovedAbility to provide informed consent.
  • RemovedWillingness to undergo study procedures including DEXA scan and laboratory assessments.
Exclusion criteria
  • RemovedKnown diagnosis of Cushing's syndrome or overt hypercortisolism.
  • RemovedCurrent or recent (within 3 months) treatment with glucocorticoids or medications affecting cortisol production (e.g., ketoconazole, metyrapone).
  • RemovedSevere hepatic impairment or renal failure.
  • RemovedPregnancy or breastfeeding.
  • RemovedKnown allergy or contraindication to osilodrostat (Isturisa).
  • RemovedParticipation in another interventional clinical trial within the last 30 days.
  • RemovedAny medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or safety.
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Eligibility Criteria largely rewritten (35 changes)
    What changed in the criteria
    • EditedDiagnosis ofAge >18 years old with confirmed mild autonomous cortisol secretion (MACS) Cushing's syndrome, defined by:
    • AddedAt least two abnormal 1 mg Dexamethasone suppression tests (Cortisol > 1.8 ug/dL at 8-9 am after taking 1 mg dexamethasone at 11 pm) with appropriate dexamethasone level for the assay (last level within 3 months before enrollment).
    • AddedHaving at least two early morning fasting ACTH <15 pg/mL (last level within 3 months before enrollment)
    • AddedPresence of at least one of the following comorbidities:
    • AddedThe presence of prediabetes or Type 2 diabetes mellitus (T2DM): fasting plasma glucose ≥100 mg/dL and/or 2-hour Oral Glucose Tolerance Test (OGTT) glucose ≥140 mg/dL, or HbA1c ≥5.7%
    • AddedSystolic hypertension is defined as a mean Systolic Blood Pressure (SBP) ≥130 mmHg after 5 min rest in a seated position (mean of 3 blood pressure measurements 5 minutes apart) irrespective of the number of anti-hypertensive medications.
    • AddedBMI >30 kg/m2
    • EditedPresenceThe presence of an adrenal adenoma confirmedor hyperplasia, as determined by imaging (CT or MRI). studies
    • AddedNegative urine pregnancy test at Baseline (urine) for women of childbearing potential
    • AddedExclusion criteria:
    • AddedHas severe, uncontrolled hypertension (mean SBP >170 mm Hg or mean Diastolic Blood Pressure (DBP) >110 mm Hg at Screening)
    • AddedHas poorly controlled DM (HbA1c >11% at Screening).
    • AddedHas abnormal liver test results (total bilirubin >1.5×ULN or elevated alanine aminotransferase or aspartate aminotransferase >3×ULN at Baseline).
    • AddedHas severe renal insufficiency (glomerular filtration rate ≤29 mL/min at Baseline).
    • AddedHas uncontrolled, clinically significant hypothyroidism or hyperthyroidism.
    • AddedHas prolonged QT interval corrected for heart rate using Fridericia's equation (QTcF) (>450 ms for men and >470 ms for women) with a normal QRS interval (<120 ms) or QTcF interval >500 ms with wide QRS interval (≥120 ms).
    • AddedHas persistent atrial fibrillation.
    • AddedHas uncorrected hypokalemia.
    • AddedHas used or plans to use any treatments for MACS within 12 weeks before Screening and throughout the study, including metyrapone, mifepristone, ketoconazole, fluconazole, or any investigational drug for the treatment of hypercortisolism.
    • AddedHas adrenocortical carcinoma, or the adrenal images are suspicious for an underlying malignancy.
    • AddedHas autonomous co-secretion of aldosterone.
    • AddedHas plans for adrenalectomy or nodulectomy during the study.
    • AddedPregnancy, lactating, or intends to become pregnant in the next 2 years.
    • AddedFemale patients of childbearing potential who cannot use a highly effective method of contraception, including all women <50 years old, women whose surgical sterilization was performed <6 months ago.
    Inclusion criteria
    • RemovedAdults aged ≥18 years.
    • RemovedSerum cortisol >1.8 µg/dL after 1 mg overnight dexamethasone suppression test (DST).
    • RemovedAbility to provide informed consent.
    • RemovedWillingness to undergo study procedures including DEXA scan and laboratory assessments.
    Exclusion criteria
    • RemovedKnown diagnosis of Cushing's syndrome or overt hypercortisolism.
    • RemovedCurrent or recent (within 3 months) treatment with glucocorticoids or medications affecting cortisol production (e.g., ketoconazole, metyrapone).
    • RemovedSevere hepatic impairment or renal failure.
    • RemovedPregnancy or breastfeeding.
    • RemovedKnown allergy or contraindication to osilodrostat (Isturisa).
    • RemovedParticipation in another interventional clinical trial within the last 30 days.
    • RemovedAny medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or safety.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07247058
Collaborators
Recordati Rare Diseases Inc
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Feb 2, 2026
Primary completion
Dec 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Pooneh Jabbaripour Sarmadian, MD
Contact
pjabbar1@jh.edu
667-208-8367
Tony Keyes
Contact
akeyes1@jhmi.edu
410-550-6259
Amir Hamrahian, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osilodrostat

Start the discussion